According to a recent LinkedIn post from TandemAI, the company’s latest TandemViz release introduces two notable capabilities aimed at drug discovery users. The post highlights in‑platform 3D design, allowing scientists to modify bound ligands in TandemSandbox and instantly visualize new molecules in the active site to accelerate structure‑guided ideation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The same post indicates that users can now train custom machine‑learning models on their own proprietary data directly within the platform. By enabling data upload, task definition, and automated generation of classification or regression models, this feature could deepen customer integration and increase switching costs.
Additional enhancements mentioned include expanded receptor infrastructure with project‑level management, zinc cofactor support with automatic ZAFF parameterisation, and improved pharmacophore filtering in TandemGen. The post also references asynchronous Lead‑RL workflows, better handling of partial‑success docking jobs, and diagnostics for self‑hosted deployments, suggesting broader workflow and reliability improvements.
For investors, these updates point to continued product development in computational chemistry and AI‑driven drug design, which may enhance TandemAI’s value proposition to biotech and pharma clients. Stronger tooling for 3D design and custom ML models could support higher platform adoption, potential upselling of advanced features, and increased platform stickiness in a competitive AI‑drug‑discovery landscape.